Literature DB >> 17938920

Can PET-CT with FDG replace contrast enhanced CT for imaging of liver metastases?

Ludwig G Strauss, Antonia Dimitrakopoulou-Strauss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17938920     DOI： 10.1007/s00259-007-0619-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  15 in total

1.  Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.

Authors:  Sophia Koukouraki; Ludwig G Strauss; Vassilios Georgoulias; Michael Eisenhut; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-09       Impact factor: 9.236

2.  Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation.

Authors:  E D Rappeport; A Loft; A K Berthelsen; P von der Recke; P Noergaard Larsen; A Mellon Mogensen; A Wettergren; A Rasmussen; J Hillingsoe; P Kirkegaard; C Thomsen
Journal:  Acta Radiol       Date:  2007-05       Impact factor: 1.990

3.  Recurrence of colorectal tumors: PET evaluation.

Authors:  L G Strauss; J H Clorius; P Schlag; B Lehner; B Kimmig; R Engenhart; M Marin-Grez; F Helus; F Oberdorfer; P Schmidlin
Journal:  Radiology       Date:  1989-02       Impact factor: 11.105

4.  Single-photon emission computed tomography (SPECT) for assessment of hepatic lesions.

Authors:  L Strauss; F Bostel; J H Clorius; E Raptou; H Wellman; P Georgi
Journal:  J Nucl Med       Date:  1982-12       Impact factor: 10.057

5.  Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.

Authors:  T J M Ruers; B S Langenhoff; N Neeleman; G J Jager; S Strijk; Th Wobbes; F H M Corstens; W J G Oyen
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

6.  Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis.

Authors:  A Dimitrakopoulou-Strauss; L G Strauss; C Burger
Journal:  J Nucl Med       Date:  2001-02       Impact factor: 10.057

Review 7.  The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.

Authors:  Bastiaan Wiering; Paul F M Krabbe; Gerrit J Jager; Wim J G Oyen; Theo J M Ruers
Journal:  Cancer       Date:  2005-12-15       Impact factor: 6.860

8.  Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis.

Authors:  Shandra Bipat; Maarten S van Leeuwen; Emile F I Comans; Milan E J Pijl; Patrick M M Bossuyt; Aeilko H Zwinderman; Jaap Stoker
Journal:  Radiology       Date:  2005-08-11       Impact factor: 11.105

9.  [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer.

Authors:  H Minn; I Soini
Journal:  Eur J Nucl Med       Date:  1989

10.  Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection?

Authors:  Ludwig G Strauss; Sven Klippel; Leyun Pan; Klaus Schönleben; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-12       Impact factor: 10.057
View more
  1 in total

1.  Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours.

Authors:  Dimitris J Apostolopoulos; Antonia Dimitrakopoulou-Strauss; Peter Hohenberger; Safwan Roumia; Ludwig G Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-12       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.